Your browser is no longer supported. Please, upgrade your browser.
Addex Therapeutics Ltd
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand5.64M Perf Week-8.26%
Market Cap58.45M Forward P/E- EPS next Y- Insider Trans- Shs Float0.26M Perf Month-10.29%
Income- PEG- EPS next Q- Inst Own0.42% Short Float1.62% Perf Quarter-2.33%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.03 Perf Half Y12.84%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range6.19 - 37.52 Perf YTD-22.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-72.36% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low67.53% ATR0.67
Employees19 Current Ratio- Sales Q/Q-79.90% Oper. Margin- RSI (14)40.70 Volatility7.42% 5.11%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.24 Prev Close10.95
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume124.15K Price10.37
Recom- SMA20-10.48% SMA50-13.75% SMA200-9.55% Volume29,399 Change-5.30%
Mar-04-21 01:00AM  
Feb-24-21 04:00AM  
Feb-17-21 01:00AM  
Feb-16-21 01:00AM  
Jan-21-21 01:00AM  
Jan-12-21 01:00AM  
Jan-11-21 04:00PM  
Jan-06-21 09:00PM  
Dec-14-20 12:22PM  
Nov-03-20 01:00AM  
Nov-02-20 01:06AM  
Sep-23-20 01:00AM  
Sep-14-20 01:00AM  
Aug-31-20 01:00AM  
Aug-27-20 01:00AM  
Aug-12-20 01:00AM  
Aug-10-20 01:00AM  
Aug-06-20 01:00AM  
Jul-20-20 01:00AM  
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.